Glioblastoma vaccine shows promise in animal study

LOS ANGELES — ImmunoCellular Therapeutics Ltd. announced March 10 that its dendritic cell-based vaccination with cancer stem cells demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

The rats were either immunized with cancer stem cells from a brain cancer tumor or the daughter cells (the bulk of the tumor), and results showed that those immunized with the CSCs had a median survival of 50 days compared to 29 days for daughter cells.

Furthermore, 30 percent of animals vaccinated against cancer stem cells demonstrated long-term survival as compared to animals vaccinated with the bulk of the tumor, all of which died.

"We are excited by the study's results, as it represents a significant step forward in the continued development of our cancer stem-cell based vaccines," said Manish Singh, president and CEO of ImmunoCellular Therapeutics.

"The data further validates our research indicating that targeting CSCs has the potential to be a highly effective method of treating various cancers."

The data also demonstrated increased Gamma-Interferon levels in animals treated with CSCs, indicating an increased immune response consistent with increase in survival further supporting the mechanism of action of this approach

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.